Food and Drug Administration (FDA) for use in adults with type 2 diabetes
Studies such as LEADER, SUSTAIN-6, REWIND, SELECT, and most recently the SOUL trial demonstrated that certain GLP-1 receptor agonists were associated with reductions in major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death.[4][5][6][7] Much of the semaglutide cardiovascular evidence, in particular, has shaped how doctors now think about these medicines
2E) and GMD, respectively, showing increased selectivity towards senescent cells in aged mouse models 63,64,65
This synergistic effect suggests that dietary strategies incorporating these carotenoids could be beneficial in preventing or alleviating DN ( 3.4 Vitamins Vitamins also have potential therapeutic effects in treating DN